Quest Diagnostics Increases Cash Dividend and Share Repurchase Authorization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy DGX?
Source: PRnewswire
- Dividend Increase: Quest Diagnostics has announced a 7.5% increase in its quarterly cash dividend from $0.80 to $0.86 per share, effective April 20, 2026, which is expected to enhance investor interest and bolster shareholder confidence.
- Annual Dividend Total: With this increase, the annual cash dividend will amount to $3.44 per share, reflecting the company's robust performance in profitability and cash flow management, thereby strengthening its market position.
- Share Repurchase Expansion: The Board has also authorized an additional $1 billion in share repurchase, supplementing the approximately $400 million available as of December 31, 2025, aimed at enhancing earnings per share and returning value to shareholders, indicating confidence in future growth.
- Market Impact Analysis: By enhancing its dividend and repurchase plans, Quest Diagnostics not only increases shareholder returns but may also attract more institutional investors, further solidifying its leadership position in the competitive healthcare diagnostics market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 201.580
Low
190.00
Averages
203.33
High
210.00
Current: 201.580
Low
190.00
Averages
203.33
High
210.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quest Launches AI Companion to Analyze Lab Data
- AI Companion Feature: Quest Diagnostics has launched the Quest AI Companion, powered by Google's Gemini technology, which analyzes up to five years of personal lab data to help users understand test results and identify potential health risks, thereby enhancing communication efficiency between patients and healthcare providers.
- User Experience Enhancement: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their results through simple inquiries, thus avoiding the privacy risks associated with uploading personal health data to public AI platforms and increasing user trust in data security.
- Strategic Collaboration: The strategic partnership between Quest and Google Cloud was established in March 2025, aiming to integrate advanced AI technologies to optimize data management and customer experience, with plans for continued collaboration to drive healthcare innovation and improve service quality for patients and providers.
- Market Demand Response: Despite the growing prevalence of AI technologies in healthcare, a Quest survey indicates that most individuals are cautious about using public AI applications to analyze personal health data; the launch of Quest AI Companion addresses patients' needs for privacy and data security, helping them better understand their lab data.
See More
Quest Launches AI Companion for Lab Data Analysis
- AI Companion Launch: Quest Diagnostics introduces Quest AI Companion, powered by Google's Gemini technology, which helps users analyze up to five years of lab data to identify potential health risks, thereby enhancing user engagement and proactive health management.
- Enhanced User Experience: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their lab results through simple inquiries, which improves communication efficiency between patients and healthcare providers.
- Data Security Assurance: Operating within the HIPAA-compliant MyQuest platform, Quest AI Companion alleviates concerns about uploading personal health data to public AI platforms, effectively safeguarding privacy and increasing user trust.
- Deepened Strategic Partnership: The strategic collaboration between Quest and Google Cloud, established in March 2025, aims to optimize data management and customer experience through the integration of advanced AI technologies, with plans to continue driving healthcare innovation.
See More
DIGI POWER X ADVANCES TO CBOE CANADA
- Graduation Announcement: DIGI POWER X graduates are set to become part of the Canadian workforce, marking a significant milestone in their educational journey.
- Program Impact: The program aims to equip graduates with essential skills and knowledge to thrive in the energy sector, contributing to Canada's growing demand for skilled professionals.
- Future Opportunities: Graduates are expected to explore various career paths within the energy industry, enhancing their prospects in a competitive job market.
- Community Engagement: The graduation event highlights the importance of community support and collaboration in fostering educational initiatives and workforce development.
See More
Quest Diagnostics Appoints New Chief Strategy and M&A Officer
- Executive Appointment: Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer, responsible for developing the company's growth strategy and leading mergers and acquisitions, which is expected to drive further advancements in the healthcare sector.
- Extensive Experience: Beauvalot brings over 20 years of experience in business strategy and transformation, having held executive roles at Danaher and Patheon where he successfully implemented numerous M&A and integration strategies, enhancing his expertise in the healthcare services field.
- Leadership Transition: Beauvalot succeeds Dermot Shorten, who has held the position since 2008 and oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories, establishing a solid foundation for the company.
- Strategic Vision: The new Chief Strategy Officer's appointment aims to leverage his rigorous approach to business integration to further propel Quest Diagnostics' organic and acquisitive growth, supporting the company's mission to create a healthier world.
See More
Quest Diagnostics CFO to Speak at Healthcare Conference
- Strategic Speaking Engagement: Quest Diagnostics' CFO Sam Samad is scheduled to speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026, where he will discuss the company's strategy, performance, and latest market developments, likely drawing attention from investors and industry experts.
- Live Webcast and Replay: The Fireside Chat and Q&A session will be webcast live on the company's investor relations page, with an archived version available within 24 hours post-event and accessible until March 25, 2026, ensuring that investors unable to attend live can still access the information.
- Company Overview: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, connecting clinicians and consumers, and focusing on smarter, simpler testing to enhance health management and drive disease identification and treatment.
- Employee and Service Reach: With nearly 57,000 employees, the company serves half of the physicians and hospitals in the U.S., providing diagnostic insights that inspire actions aimed at improving quality of life, reflecting its leadership position in the healthcare industry.
See More
Quest Diagnostics CFO to Speak at Healthcare Conference
- Strategic Address: Quest Diagnostics CFO Sam Samad will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026, discussing the company's strategy, performance, and market trends, which is expected to attract investor attention and enhance the company's profile.
- Live Webcast: The Fireside Chat and Q&A session will be webcast live on the company's investor relations page, increasing transparency and providing investors with direct interaction opportunities, likely boosting investor confidence.
- Replay Availability: An archived version of the event will be available within 24 hours post-event until March 25, 2026, ensuring that investors who cannot attend live can still access critical information, thereby broadening the reach of the communication.
- Company Impact: Quest Diagnostics serves half of the physicians and hospitals in the U.S. annually, connecting clinicians with consumers and focusing on smarter testing to improve healthcare management, showcasing its significant role in the healthcare industry.
See More
Quest Launches AI Companion to Analyze Lab Data
- AI Companion Feature: Quest Diagnostics has launched the Quest AI Companion, powered by Google's Gemini technology, which analyzes up to five years of personal lab data to help users understand test results and identify potential health risks, thereby enhancing communication efficiency between patients and healthcare providers.
- User Experience Enhancement: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their results through simple inquiries, thus avoiding the privacy risks associated with uploading personal health data to public AI platforms and increasing user trust in data security.
- Strategic Collaboration: The strategic partnership between Quest and Google Cloud was established in March 2025, aiming to integrate advanced AI technologies to optimize data management and customer experience, with plans for continued collaboration to drive healthcare innovation and improve service quality for patients and providers.
- Market Demand Response: Despite the growing prevalence of AI technologies in healthcare, a Quest survey indicates that most individuals are cautious about using public AI applications to analyze personal health data; the launch of Quest AI Companion addresses patients' needs for privacy and data security, helping them better understand their lab data.
See More
Quest Launches AI Companion for Lab Data Analysis
- AI Companion Launch: Quest Diagnostics introduces Quest AI Companion, powered by Google's Gemini technology, which helps users analyze up to five years of lab data to identify potential health risks, thereby enhancing user engagement and proactive health management.
- Enhanced User Experience: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their lab results through simple inquiries, which improves communication efficiency between patients and healthcare providers.
- Data Security Assurance: Operating within the HIPAA-compliant MyQuest platform, Quest AI Companion alleviates concerns about uploading personal health data to public AI platforms, effectively safeguarding privacy and increasing user trust.
- Deepened Strategic Partnership: The strategic collaboration between Quest and Google Cloud, established in March 2025, aims to optimize data management and customer experience through the integration of advanced AI technologies, with plans to continue driving healthcare innovation.
See More
DIGI POWER X ADVANCES TO CBOE CANADA
- Graduation Announcement: DIGI POWER X graduates are set to become part of the Canadian workforce, marking a significant milestone in their educational journey.
- Program Impact: The program aims to equip graduates with essential skills and knowledge to thrive in the energy sector, contributing to Canada's growing demand for skilled professionals.
- Future Opportunities: Graduates are expected to explore various career paths within the energy industry, enhancing their prospects in a competitive job market.
- Community Engagement: The graduation event highlights the importance of community support and collaboration in fostering educational initiatives and workforce development.
See More
Quest Diagnostics Appoints New Chief Strategy and M&A Officer
- Executive Appointment: Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer, responsible for developing the company's growth strategy and leading mergers and acquisitions, which is expected to drive further advancements in the healthcare sector.
- Extensive Experience: Beauvalot brings over 20 years of experience in business strategy and transformation, having held executive roles at Danaher and Patheon where he successfully implemented numerous M&A and integration strategies, enhancing his expertise in the healthcare services field.
- Leadership Transition: Beauvalot succeeds Dermot Shorten, who has held the position since 2008 and oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories, establishing a solid foundation for the company.
- Strategic Vision: The new Chief Strategy Officer's appointment aims to leverage his rigorous approach to business integration to further propel Quest Diagnostics' organic and acquisitive growth, supporting the company's mission to create a healthier world.
See More
Quest Diagnostics CFO to Speak at Healthcare Conference
- Strategic Speaking Engagement: Quest Diagnostics' CFO Sam Samad is scheduled to speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026, where he will discuss the company's strategy, performance, and latest market developments, likely drawing attention from investors and industry experts.
- Live Webcast and Replay: The Fireside Chat and Q&A session will be webcast live on the company's investor relations page, with an archived version available within 24 hours post-event and accessible until March 25, 2026, ensuring that investors unable to attend live can still access the information.
- Company Overview: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, connecting clinicians and consumers, and focusing on smarter, simpler testing to enhance health management and drive disease identification and treatment.
- Employee and Service Reach: With nearly 57,000 employees, the company serves half of the physicians and hospitals in the U.S., providing diagnostic insights that inspire actions aimed at improving quality of life, reflecting its leadership position in the healthcare industry.
See More
Quest Diagnostics CFO to Speak at Healthcare Conference
- Strategic Address: Quest Diagnostics CFO Sam Samad will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026, discussing the company's strategy, performance, and market trends, which is expected to attract investor attention and enhance the company's profile.
- Live Webcast: The Fireside Chat and Q&A session will be webcast live on the company's investor relations page, increasing transparency and providing investors with direct interaction opportunities, likely boosting investor confidence.
- Replay Availability: An archived version of the event will be available within 24 hours post-event until March 25, 2026, ensuring that investors who cannot attend live can still access critical information, thereby broadening the reach of the communication.
- Company Impact: Quest Diagnostics serves half of the physicians and hospitals in the U.S. annually, connecting clinicians with consumers and focusing on smarter testing to improve healthcare management, showcasing its significant role in the healthcare industry.
See More
